ALPRE Stock Overview
Develops and sells medical techniques and mathematical models. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Predilife S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.06 |
| 52 Week High | €24.00 |
| 52 Week Low | €3.32 |
| Beta | 0.36 |
| 11 Month Change | 12.78% |
| 3 Month Change | -17.14% |
| 1 Year Change | -32.33% |
| 33 Year Change | -38.95% |
| 5 Year Change | -48.93% |
| Change since IPO | -56.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALPRE | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 4.6% | -7.7% | -0.3% |
| 1Y | -32.3% | -26.4% | -3.5% |
Return vs Industry: ALPRE underperformed the French Biotechs industry which returned -26.5% over the past year.
Return vs Market: ALPRE underperformed the French Market which returned -2.5% over the past year.
Price Volatility
| ALPRE volatility | |
|---|---|
| ALPRE Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALPRE's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALPRE's weekly volatility has decreased from 31% to 7% over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 19 | Stephane Ragusa | www.predilife.com |
Predilife S.A. develops and sells medical techniques and mathematical models. The company provides prevention and breast check-up tests. Its products include MammoRisk, a test for predicting the development of breast cancer based on the patient’s individual risk; and DenSeeMammo, a breast density measurement software, as well as a medical device for the prediction of prostate cancer risk.
Predilife S.A. Fundamentals Summary
| ALPRE fundamental statistics | |
|---|---|
| Market cap | €15.61m |
| Earnings (TTM) | -€4.66m |
| Revenue (TTM) | €310.87k |
48.5x
P/S Ratio-3.2x
P/E RatioIs ALPRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALPRE income statement (TTM) | |
|---|---|
| Revenue | €310.87k |
| Cost of Revenue | €356.47k |
| Gross Profit | -€45.60k |
| Other Expenses | €4.62m |
| Earnings | -€4.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.25 |
| Gross Margin | -14.67% |
| Net Profit Margin | -1,500.20% |
| Debt/Equity Ratio | -81.8% |
How did ALPRE perform over the long term?
See historical performance and comparison